Stifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $58.00 (from $75.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE